Nexvet Biopharma plc
Nexvet Biopharma plc (NVET): 5 pipeline candidates · ~8 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
8.2 months
D/E 0.18 · 0% dilution
Lead: Phase 3
5 candidates
N/A
N/A
A transparent, data-derived signal for Nexvet Biopharma plcacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$14.5M
Quarterly Burn
$5.8M
Runway
8.2 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| anti-pd-1 mabs | Preclinical |
| anti-tnf mabs | Preclinical |
| frunevetmab | Phase 2 |
| nv-03 | Preclinical |
| ranevetmab | Phase 3 |
Frequently asked questions
How many drug candidates are in Nexvet Biopharma plc's pipeline?
Nexvet Biopharma plc (NVET) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Nexvet Biopharma plc's lead drug candidate?
Nexvet Biopharma plc's most advanced tracked candidate is anti-pd-1 mabs (Preclinical) for cancer in dogs.
What is Nexvet Biopharma plc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Nexvet Biopharma plc has approximately 8.2 months of cash runway.
Who is the CEO of Nexvet Biopharma plc?
Mark Heffernan, Ph.D. is the chief executive officer of Nexvet Biopharma plc (NVET).
Get the full picture on Nexvet Biopharma plc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.